Earnings Feed
Start Free
Home/Filings/4/0001209191-22-040266
4//SEC Filing

Pelzer Robert 4

Accession 0001209191-22-040266

CIK 0001290149other
View on SEC.govCompany Profile

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 4:41 PM ET

Size

19.6 KB

Accession

0001209191-22-040266

Insider Transaction Report

Form 4
Period: 2022-07-01
Sierra Oncology, Inc.SRRA
Pelzer Robert
Director
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−750→ 0 total
    Exercise: $26.40Exp: 2029-06-11→ Common Stock (750 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−671→ 0 total
    Exercise: $268.20Exp: 2025-06-17→ Common Stock (671 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−625→ 0 total
    Exercise: $45.20Exp: 2027-06-13→ Common Stock (625 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−970→ 0 total
    Exercise: $82.40Exp: 2026-06-16→ Common Stock (970 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−625→ 0 total
    Exercise: $130.80Exp: 2028-06-12→ Common Stock (625 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−16,686→ 0 total
    Exercise: $13.98Exp: 2030-06-09→ Common Stock (16,686 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2022-07-01−6,000→ 0 total
    Exercise: $18.11Exp: 2031-06-08→ Common Stock (6,000 underlying)
Footnotes (9)
  • [F1]The option fully vested on June 18, 2016.
  • [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
  • [F3]The option fully vested on June 16, 2017.
  • [F4]The option fully vested on June 13, 2018.
  • [F5]Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
  • [F6]The option fully vested on June 12, 2019.
  • [F7]The option fully vested on June 11, 2020.
  • [F8]The option fully vested on June 9, 2021.
  • [F9]The option fully vested on June 8, 2022.

Documents

1 file

Issuer

Sierra Oncology, Inc.

CIK 0001290149

→
Entity typeother

Related Parties

1
  • filerCIK 0001297500

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 4:41 PM ET
Size
19.6 KB
View on SEC.gov